Saltar al contenido
Merck

410957

3-Isobutyl-1-methylxanthine

≥98% (HPLC), solid, cAMP and cGMP phosphodiesterase inhibitor, Calbiochem®

Sinónimos:

3-Isobutyl-1-methylxanthine, IBMX

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C10H14N4O2
Número CAS:
Peso molecular:
222.24
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


Nombre del producto

3-Isobutyl-1-methylxanthine, A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM).

Quality Level

description

RTECS - ZD8500000

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

white

solubility

ethanol: 10 mg/mL, DMSO: 100 mM, methanol: 50 mg/mL

shipped in

ambient

storage temp.

−20°C

SMILES string

[n]1(c2nc[nH]c2[c]([n]([c]1=O)C)=O)CC(C)C

InChI

1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)

InChI key

APIXJSLKIYYUKG-UHFFFAOYSA-N

General description

A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM). Also acts as an adenosine receptor antagonist. Reported to inhibit TNF-α expression in adipocyte precursor cells.
A non-specific, cell-permeable inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM). Also acts as an adenosine receptor antagonist. Reported to inhibit TNFα expression in adipocyte precursor cells.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
cAMP and cGMP phosphodiesterases
Product does not compete with ATP.
Reversible: no
Target IC50: 2-50 µM against cAMP and cGMP phosphodiesterases

Preparation Note

Following reconstitution in ethanol or methanol, refrigerate (4°C). Following reconstitution in DMSO, aliquot and freeze (-20°C). Ethanol/methanol and DMSO stock solutions are stable for up to 6 months at 4°C or -20°C, respectively.
Heating may be required to achieve complete solubilization.

Other Notes

Hube, F., et al. 1999. Horm. Metab. Res.31, 359.
Morgan, A.J., et al. 1993. Biochem. Pharmacol.45, 2373.
Scamps, F., et al. 1993. Eur. J. Pharmacol. 244, 119.
Turner, N.C., et al. 1993. Br. J. Pharmacol. 108, 876.
Tamura, T., et al. 1991. J. Gen. Physiol. 98, 95.
Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150.
Russell, T.R. 1979. Proc. Natl. Acad. Sci. USA76, 4451.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)


Still not finding the right product?

Explore all of our products under


Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Jiang Li et al.
Antioxidants (Basel, Switzerland), 13(5) (2024-05-25)
Hypertension reduces the bioavailability of vascular nitric oxide (NO) and contributes to the onset of vascular dementia (VaD). A loss of NO bioavailability increases inflammation and oxidative stress. 2-(4-Methylthiazol-5-yl) ethyl nitrate hydrochloride (W1302) is a novel nitric oxide donor (NOD)
Jiankun Xu et al.
Bioactive materials, 8, 95-108 (2021-09-21)
Magnesium metal and its alloys are being developed as effective orthopedic implants; however, the mechanisms underlying the actions of magnesium on bones remain unclear. Cystic fibrosis, the most common genetic disease in Caucasians caused by the mutation of CFTR, has
H Ji
Methods in molecular medicine, 51, 363-377 (2001-01-01)
Angiotensin type-1 receptors (AT(1) receptors) mediate various physiological actions of angiotensin (Ang II) via multiple-signal transduction pathways (1). In addition to the phospholipase C pathway and dihydropyridine-sensitive voltage-dependent calcium channels, AT(1) receptors can couple to inhibition of adenylate cyclase via